ELVN Q4 2023 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$19M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$272M

Total Liabilities

$26M

Stockholders' Equity

$246M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$10M	-123.6%
Net Income	-$19M	-$10M	-102.8%